bioroom
-
Portfolio
Saol Therapeutics expands its dichloroacetate (DCA; SL-1009) IP portfolio in glioblastoma and rare pediatric cancers
By signing an agreement with Medosome Biotec By providing support for the treatment of GBM in clinical trials at the…
Read More » -
Portfolio
Mediar Therapeutics announces $105 million in funding to advance portfolio of best-in-class fibrosis therapies
The company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression The portfolio includes three targets,…
Read More » -
Portfolio
NeoGenomics expands its NGS portfolio with the launch of Neo Comprehensive(TM) – Solid Tumor CGP and Neo Comprehensive(TM) – Myeloid Disorders CGP
FT. MYERS, FL / ACCESSWIRE / March 13, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and…
Read More » -
Business
Philips appoints Julia Strandberg as Chief Business Leader of the Connected Care business
Amsterdam, Netherlands – Royal Phillips (NYSE: PHG, AEX: PHIA), a global leader in healthcare technology, today announced the appointment of…
Read More »